Are stents still a useful therapy for benign prostatic hyperplasia?

Current Opinion in Urology

Volumn 13, Issue 1, 2003, Pages 51-57

  Ogiste, Jason S ^a   Cooper, Kimberly ^a   Kaplan, Steven A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Benign prostatic hyperplasia; Stents

Indexed keywords

ENDOPROSTHESIS; HUMAN; LASER SURGERY; MINIMALLY INVASIVE SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATIC STENT; REVIEW; STENT; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION; TREATMENT FAILURE; URINE RETENTION;

AGED; DIATHERMY; HUMANS; LASER SURGERY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STENTS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 0037243421     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200301000-00009     Document Type: Review

References (47)

1. Dychtwald K. 'Age power': how the new-old will transform medicine in the 21st century. Geriatrics 1999; 54:22-27.
2. McConnell JD. Epidemiology, etiology, pathophysiology, and diagnosis of benign prostatic hyperplasia. In: Campbell's urology, 7th ed. Walsh PC, Retik AB, Vaughan DE, Wein AJ (editors). New York: W.B. Saunders Company; 1998; pp. 1429-1452.
3. Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology 1998; 51 (Suppl. 4A):23-31.
4. McConnell JD, Barry MD, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment-clinical practice guidelines. AHCPR Publication No. 94-0583. Rockville, Maryland: Agency for Healthcare Policy and Research; 1994
5. Ala-Opas MY, Mertikainan PM. Evaluation of immediate and late results of transurethral resection of the prostate. Scand J Nephrol 1993; 27:235-239.
6. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and post-operative complications. A cooperative study of thirteen participating institutions evaluating 3,885 patients. J Urol 1989; 141:243-247.
7. Plentka L, Loghem JV, Hahn E, et al. Comorbidities and perioperative complications among patients with surgically treated benign prostatic hyperplasia. Urology 1991; 38 (Suppl. 1):43-48.
8. Estey ET, Mador ER, McPhee MS, et al. A review of 1486 transurethral resection of the prostate in a teaching hospital. Can J Surg 1993; 36:37-40.
9. Chute CG, Stephenson WP, Guess HA, et al. Benign prostatic hyperplasia: a population-based study. Eur Urol 1991; 20 (Suppl. 2):11-17.
10. Lam JS, Volpe MA, Kaplan SA. The use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients. Curr Urol Rep 2001; 2:277-284.
11. Kletscher BA, Oesterling JE. Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia. Urol Clin North Am 1995; 22:423-430.
12. Parikh AM, Milroy EJG. Precautions and complications in the use of the UroLume wallstent. Eur Urol 1995; 27:1-7.
13. Song HY, Cho KS, Sung KB, et al. Self-expandable metallic stents in high-risk patients with benign prostatic hyperplasia: long-term follow-up. Radiology 1995; 195:655-660.
14. Chiou RK, Chen WS, Akbari A, et al. Long-term outcome of prostatic stent treatment for benign prostatic hyperplasia. Urology 1996; 48:589-593.
15. Fitzpatrick JM, Mebust WK. Minimally invasive and endoscopic management of benign prostatic hyperplasia. In: Campbell's urology, 8th ed. Walsh PC, Retik AB, Vaughan DE, Wein AJ (editors). New York: W.B. Saunders Company; 2002. pp. 1380-1417. This study gives a comprehensive review of the data as they pertain to the use of stents and other minimally invasive therapies in prostatic pathology. It details nicely the progression of historical data on each subject to relatively current, palpable issues in each area. An excellent resource with balanced data for the appropriate counselling of patients considering stent placement.
16. Williams G, White R. Experience with the Memotherm™ permanently implanted prostatic stent. Br J Urol 1995; 76:337-340.
17. Pomer S, Dobrowolski ZF. The therapy of benign prostatic hyperplasia using less-invasive procedures: the current situation. BJU Int 2002; 89:773-775.
18. Bruskewitz R, Issa MM, Roehrborn CG, et al. A prospective, randomized, 1-year clinical trial comparing transurethral needle ablation (TUNA) to TURP for the treatment of symptomatic BPH. J Urol 1998; 159:1588-1594.
19. Issa MM, Oesterling JE. Radiofrequency thermal therapy for BPH by transurethral needle ablation of the prostate. In: Benign prostatic hyperplasia. Narayan P (editor). London: Churchill Livingstone; 2000. pp. 269-280.
20. Bruskewitz R, Issa MM, Roehborn CG, et al. A prospective, randomized 1-year clinical trial comparing TUNA to TURP for the treatment of symptomatic BPH. J Urol 1998; 159:158-193.
21. Bergamashi F, Manzo M, Antieri G, et al. Five year experience using TUNA in 204 BPH patients. J Urol 2000; 163:A1480.
22. Larson TR, Bostwick DG, Corica A. Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with BPH. Urology 1996; 47:463-469.
23. Larson TR, Blute ML, Tri JL, et al. Contrasting heating patterns and efficacy of the Prostation and Targis microwave antennae for thermal treatment of BPH. Urology 1998; 51:908-915.
24. Larson TR, Collins JM. Increased prostatic blood flow in response to microwave thermal treatment: preliminary findings in two patients with BPH. Urology 1995; 46:584-590.
25. Perachino M, Bozzo W, Puppo P, et al. Does transurethral thermotherapy induce a long-term alpha blockade? Eur Urol 1993; 23:299-301.
26. Brehmer M, Wiksell H, Kin A. Sham treatment compared to 30 and 60 minutes of thermotherapy in patients with BPH. A randomized study. Br J Urol 1999; 84:292-296.
27. De La Rosette J, De Wildt M, Alvizatos G, et al. TUMT in benign prostatic hyperplasia. Placebo vs. TUMT. Urology 1994; 44:58-63.
28. Blute ML, Patterson DE, Segura JW, et al. Transurethral microwave thermotherapy vs. sham treatment: a double-blind, randomized study. J Endourol 1996; 10:565-573.
29. Nawrocki JD, Bell TJ, Lawrence WT, et al. A randomized controlled trial of transurethral microwave therapy. Br J Urol 1997; 79:389-393.
30. d'Ancona FC, Francisca EA, Witjes WP, et al. High-energy thermotherapy versus transurethral resection in the treatment of BPH: results of a prospective study with 1-year of follow-up. J Urol 1997; 158:120-125.
31. Keoghane SR, Cranston DW, Lawrence KC, et al. The Oxford Laser Trial: a randomized, controlled trial of contact vaporization of the prostate against transurethral resection: preliminary results. Br J Urol 1996; 77:382-385.
32. Keoghane SR, Lawrence KC, Gray A, et al. A double-blind, randomized controlled trial and economic evaluation of transurethral resection vs. contact laser vaporization for benign prostatic enlargement. A 3-year follow-up. BJU Int 2000; 85:74-78.
33. Van Melick HH, Van Venrooij GE, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with BPH: urodynamic effects. J Urol 2002; 168:1058-1062.
34. Tan AH, Gilling PJ. Holmium Laser prostatectomy: current techniques. Urology 2002; 60:152-156.
35. Jordan GH. Urolume endoprosthesis for the treatment of recurrent bulbous urethral stricture. AUA Update Series 1999; 29:18-23.
36. Kemppainen E, Talja M, Riihela M, et al. A bioresorbable stent: an experimental study. Urol Res 1993; 21:235-238.
37. Isotalo T, Talja M, Hellstrom P, et al. A double-blind, randomized, placebo-cotrolled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from BPH. BJU Int 2001; 88:30-34.
38. Poulsen AL, Shou J, Tammela T, et al. Memokath: a second generation of intraprostatic spirals. Br J Urol 1993; 72:331-337.
39. Yachia D, Beyar M, Aridogan IA. A new large caliber self-expanding and self retaining temporary intraprostatic stent (Prostacoil) in the treatment of prostatic obstruction. Br J Urol 1994; 74:47-52.
40. Dahlstrand C, Grundtman S, Pettersson S. High energy TUMT for large severely obstructing prostates and the use of biodegradable stents to avoid catheterization after treatment. Br J Urol 1997; 79:907-909.
41. Petas A, Talja M, Tammela T, et al. A randomized study to compare biodegradable self-reinforced polyglycolic acid spiral stents to suprapubic and indwelling catheters after visual laser ablation of the prostate. J Urol 1997; 157:173-176.
42. Laaksorvirta S, Talja M, Valimaa T, et al. Expansion and bioabsorption of the self-reinforced lactic and glycolic acid copolymer prostatic spiral stent. J Urol 2001; 166:919-922.
43. Laaksorvirta S, Marita L, Taina I, et al. Rabbit muscle and urethral in situ biocompatibility properties of the self-reinforced L-lactide-glycolic acid copolymer 80:20 spiral stent. J Urol 2002; 167:1527-1531.
44. Zivan I, Stein A. New modality for treatment of resistant anastamotic strictures after radical prostatectomy: UroLume urethral stent. J Endourol 2001; 15:869-871.
45. Wilson TS, Gary LE, Dmochowski RR. UroLume stents: lessons learned. J Urol 2002; 167:2477-2480.
46. Elliott DS, Boone TB. Combined stent and artificial urinary sphincter for management of severe recurrent bladder neck contracture and stress incontinence after prostatectomy: a long-term evaluation. J Urol 2001; 165:413-415.
47. Sertcelik N, Sagnak A, Imamoglu M. The use of self-expanding metallic urethral stents in the treatment of recurrent bulbar urethral strictures: long-term results. BJU Int 2000; 86:686-689.